The present disclosure provides a composition that may find utility in management of COVID-19. The inventors of the present disclosure surprisingly observed that ingredients of the composition of the present disclosure exhibit functional synergy therebetween, wherein the composition prevents virus replication and/or Virus entry into human cells, either wholly or in part, while modulating immune response of the patient. Hence, the composition of the present disclosure holds potential for wide spread usage in management of COVID-19, either alone or in combination with other preventive or palliative/symptomatic or therapeutic strategies.

The present disclosure provides a composition that may find utility in management of COVID-19. The inventors of the present disclosure surprisingly observed that ingredients of the composition of the present disclosure exhibit functional synergy therebetween, wherein the composition prevents virus replication and/or Virus entry into human cells, either wholly or in part, while modulating immune response of the patient. Hence, the composition of the present disclosure holds potential for wide spread usage in management of COVID-19, either alone or in combination with other preventive or palliative/symptomatic or therapeutic strategies.

Provided is a method for preventing and alleviating inflammatory bowel disease by administering a composition including puer tea extract as an active ingredient to a subject in need thereof. Puer tea extract of the present disclosure showed an effect of improving damaged colonic tissue in a mouse model of acute ulcerative colitis induced by dextran sulfate sodium (DSS), and showed an inhibitory effect on clinical symptoms of the disease activity index (DAT) of weight loss, diarrhea, and rectal bleeding. In addition, puer tea extract inhibited the expression of inflammatory cytokines TNF-α and IL-6 in the colonic tissue and inhibited the inflammatory response through inhibition of the activity of NF-κB, an anti-inflammatory mechanism. In addition, the DPPH free radical and ABTS free radical scavenging ability increased proportionally as the concentration of puer tea extract increased at the cellular level, and COX-2 expression was inhibited in LPS-activated macrophages.

Provided is a method for preventing and alleviating inflammatory bowel disease by administering a composition including puer tea extract as an active ingredient to a subject in need thereof. Puer tea extract of the present disclosure showed an effect of improving damaged colonic tissue in a mouse model of acute ulcerative colitis induced by dextran sulfate sodium (DSS), and showed an inhibitory effect on clinical symptoms of the disease activity index (DAT) of weight loss, diarrhea, and rectal bleeding. In addition, puer tea extract inhibited the expression of inflammatory cytokines TNF-α and IL-6 in the colonic tissue and inhibited the inflammatory response through inhibition of the activity of NF-κB, an anti-inflammatory mechanism. In addition, the DPPH free radical and ABTS free radical scavenging ability increased proportionally as the concentration of puer tea extract increased at the cellular level, and COX-2 expression was inhibited in LPS-activated macrophages.

The present invention relates to novel green tea water soluble film composition comprising a) green tea extract, b) water soluble polymer mixture consisting of sodium carboxymethyl cellulose and sodium alginate, and c) additives. Green tea is conveniently prepared by dissolving the novel water soluble green tea film of the said invention in hot water.

The present invention relates to novel green tea water soluble film composition comprising a) green tea extract, b) water soluble polymer mixture consisting of sodium carboxymethyl cellulose and sodium alginate, and c) additives. Green tea is conveniently prepared by dissolving the novel water soluble green tea film of the said invention in hot water.

Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.

Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.

Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.

Kombucha tea faces many challenges concerning its use for its health benefits, such as standardization, as well as the determination of a specific dosage form appropriate to the intended use. Kombucha tea, as a fermented, alcohol-containing beverage that relies on a complex combination of living yeast and bacteria for production, is especially difficult to administer. The present invention provides a consistent, standardized dosage form and novel combinations of a traditional medicinal drink that is otherwise unsuitable for widespread natural medicine. By providing kombucha as a soft, chewable and orally dissolvable and/or disintegrable compositions, such as a gummie, a gummie with probiotics, or a gummy made from tapioca syrup, a unique, desirable flavor and mouthfeel is obtained and which is also alcohol free. This expands the number of people who can enjoy the benefits of the traditional tea.